Tag Archives: recurrence

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

BACKGROUND: Most women with advanced epithelial ovarian cancer will ultimately develop recurrent disease after completion of initial treatment with primary surgery and adjuvant chemotherapy. Secondary cytoreductive surgery may have survival … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer

First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and about 40—50% of women who respond to initial treatment relapse within 2 years. In the recurrent … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer

BACKGROUND: Cisplatin is a highly effective chemotherapeutic agent against epithelial ovarian cancer but is associated with significant toxicities. SPI-77 is a liposomal pegylated formulation of cisplatin that was developed to … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Why cancer drugs lose their power

For 30 years, the chemotherapy drug cisplatin has been one of doctors’ first lines of defense against tumors, especially those of the lung, ovary and testes. While cisplatin is often … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Magee-Womens Hospital of UPMC Launches Clinical Trial for Patients with Recurrent Ovarian Cancer

Magee-Womens Hospital of UPMC will be the only site in Western Pennsylvania for a clinical trial of ABT-888, a drug previously proven in combination treatments to improve chemotherapy’s effectiveness by … Continue reading 

Posted in News | Also tagged , , , , | Leave a comment

Tamoxifen for relapse of ovarian cancer

BACKGROUND: Tamoxifen is an important drug for treating breast cancer. Ovarian cancer cells are known to possess receptors for hormones and may thus also respond to tamoxifen. OBJECTIVES: Tamoxifen is … Continue reading 

Posted in Blog, News | Also tagged , , , | Leave a comment

Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer (Arch Gynecol Obstet)

OBJECTIVE: To evaluate the accuracy of integrated FDG-PET/CT and tumor markers for the depiction of recurrent ovarian carcinoma. METHODS: Patients with pathologically proven ovarian cancer, who underwent cytoreductive surgery and … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Patient Surveillance After Ovarian Cancer Treatment Is Variable: Presented at SSO

New data indicate that there is marked variability in the intensity of patient surveillance after curative-intent treatment for ovarian cancer. The results were released here on March 6 at the … Continue reading 

Posted in News | Also tagged | Leave a comment

Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias? (Gynecol Oncol)

OBJECTIVE: To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete … Continue reading 

Posted in News | Also tagged | Leave a comment